Abstract
We recently reported on the development of a novel series of BRAF inhibitors based on a tripartite A−B−C system characterized by a para-substituted central aromatic core connected to an imidazo[4,5]pyridin-2-one scaffold and a substituted urea linker. Here, we present a new series of BRAF inhibitors in which the central phenyl ring connects to the hinge binder and substrate pocket of BRAF with a meta-substitution pattern. The optimization of this new scaffold led to the development of low-nanomolar inhibitors that permits the use of a wider range of linkers and terminal C rings while enhancing the selectivity for the BRAF enzyme in comparison to the para series.
| Original language | English |
|---|---|
| Pages (from-to) | 1964-1978 |
| Number of pages | 15 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 53 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 11 Feb 2010 |
Research Beacons, Institutes and Platforms
- Manchester Cancer Research Centre